Form 8-K - Current report:
SEC Accession No. 0001437749-25-006555
Filing Date
2025-03-07
Accepted
2025-03-07 07:07:52
Documents
18
Period of Report
2025-03-04
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K nby20250307_8k.htm   iXBRL 8-K 39523
2 EXHIBIT 10.1 ex_786880.htm EX-10.1 76358
3 EXHIBIT 99.1 ex_786881.htm EX-99.1 12448
8 logo.jpg GRAPHIC 3886
9 lucidlogo.jpg GRAPHIC 10529
  Complete submission text file 0001437749-25-006555.txt   310393

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA nby-20250304.xsd EX-101.SCH 3401
5 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE nby-20250304_def.xml EX-101.DEF 11804
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE nby-20250304_lab.xml EX-101.LAB 15858
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE nby-20250304_pre.xml EX-101.PRE 12019
20 EXTRACTED XBRL INSTANCE DOCUMENT nby20250307_8k_htm.xml XML 2949
Mailing Address 2000 POWELL STREET, SUITE 1150 EMERYVILLE CA 94608
Business Address 2000 POWELL STREET, SUITE 1150 EMERYVILLE CA 94608 (510) 899-8800
NovaBay Pharmaceuticals, Inc. (Filer) CIK: 0001389545 (see all company filings)

EIN.: 680454536 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-33678 | Film No.: 25717547
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)